Company Overview and News

 
GEE TERM LOAN AND SECURITY AGREEMENT

2017-09-01 sec.gov
gee_ex101.htm EXHIBIT 10.1   CONSENT TO EXTENSION OF WAIVER TO REVOLVING CREDIT, TERM LOAN AND SECURITY AGREEMENT   CONSENT, dated as of August 31, 2017 (this "Consent"), to extension of the Waiver, dated as of August 14, 2017 (as amended, amended and restated, restated, supplemented or otherwise modified from time to time, the "Waiver"), to the Revolving Credit, Term Loan and Security Agreement dated as of March 31, 2017 (as amended, amended and restated, restated, supplemented or otherwise mod

 
GEE FORM 8-K (Current Report/Significant Event)

2017-09-01 sec.gov
job_8k.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): August 31, 2017   GEE GROUP, INC. (Exact name of registrant as specified in its charter)   Illinois 1-05707 36-6097429 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.

 
GEE FORM 8-K (Current Report/Significant Event)

2017-08-18 sec.gov
gee_8k.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): August 16, 2017   GEE GROUP, INC. (Exact name of registrant as specified in its charter)   Illinois 1-05707 36-6097429 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.

 
GEE PRESS RELEASE

2017-08-17 sec.gov
gee_ex991.htm EXHIBIT 99.1   GEE Group Announces Results for the Fiscal 2017 Third Quarter   Naperville, IL, August 14, 2017 /Accesswire / – GEE Group Inc. (NYSE American: JOB) (“the Company” or “GEE Group”), a provider of professional staffing services and human resource solutions, today announced results for the third quarter ended June 30, 2017.   2017 Fiscal Third Quarter Highlights   ●    Revenue for the fiscal 2017 third quarter was approximately $46.

 
GEE FORM 8-K (Current Report/Significant Event)

2017-08-17 sec.gov
gee_8k.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): August 14, 2017   GEE GROUP, INC (Exact name of registrant as specified in its charter)   Illinois 1-05707 36-6097429 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.

 
GEE CERTIFICATION

2017-08-14 sec.gov
job_ex322.htm EXHIBIT 32.02   CERTIFICATIONS PURSUANT TO SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE   In connection with the Quarterly Report of GEE Group Inc. (the “Company”) on Form 10-Q for the nine-month period ended June 30, 2017 filed with the Securities and Exchange Commission (the “Report”), the undersigned hereby certifies, in his capacity as an officer of the Company, pursuant to 18 U.

 
GEE CERTIFICATION

2017-08-14 sec.gov
job_ex321.htm EXHIBIT 32.01   CERTIFICATIONS PURSUANT TO SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE   In connection with the Quarterly Report of GEE Group Inc. (the “Company”) on Form 10-Q for the nine-month period ended June 30, 2017 filed with the Securities and Exchange Commission (the “Report”), the undersigned hereby certifies, in his capacity as an officer of the Company, pursuant to 18 U.

 
GEE CERTIFICATION

2017-08-14 sec.gov
job_ex312.htm EXHIBIT 31.02   CERTIFICATION   I, Andrew J. Norstrud, certify that:   1. I have reviewed this Form 10-Q quarterly report for the nine-month period ended June 30, 2017 of GEE Group Inc.;     2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this r

 
GEE CERTIFICATION

2017-08-14 sec.gov
job_ex311.htm EXHIBIT 31.01   CERTIFICATION   I, Derek Dewan, certify that:   1. I have reviewed this Form 10-Q quarterly report for the nine-month period ended June 30, 2017 of GEE Group Inc.;     2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 
GEE WAIVER TO THE REVOLVING CREDIT, TERM LOAN AND SECURITY AGREEMENT

2017-08-14 sec.gov
job_ex101.htm EXHIBIT 10.1    WAIVER TO REVOLVING CREDIT, TERM LOAN AND SECURITY AGREEMENT   WAIVER, dated as of August 14, 2017 (this "Waiver"), to the Revolving Credit, Term Loan and Security Agreement dated as of March 31, 2017 (as amended, amended and restated, restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), by and among GEE GROUP INC., an Illinois corporation ("Holdings"), SCRIBE SOLUTIONS, INC.

 
GEE FORM 10-Q (Quarterly Report)

2017-08-14 sec.gov
job_10q.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   FORM 10-Q   x QUARTERLY REPORT UNDER SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   For the quarterly period ended June 30, 2017   OR   o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934   Commission File Number 1-05707   GEE GROUP INC. (Exact name of registrant as specified in its charter)   Illinois 36-6097429 (State or other jurisdiction of incorporation

 
GEE DEFR 14A

2017-07-12 sec.gov
job_def14a.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________   SCHEDULE 14A   Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934   Filed by the Registrant x Filed by a Party other than the registrant o   Check the appropriate box:   ¨ Preliminary Proxy Statement     o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))     x Definitive Proxy Statement     o Definitive Additional Materials

 
GEE DEF 14A

2017-07-10 sec.gov
job_def14a.htm   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________   SCHEDULE 14A   Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934   Filed by the Registrant x Filed by a Party other than the registrant o   Check the appropriate box:   ¨ Preliminary Proxy Statement     o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))     x Definitive Proxy Statement     o Definitive Additional Materials

 
GEE CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

2017-06-21 sec.gov
EXHIBIT 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM  We hereby consent to the incorporation by reference in this Registration Statement on Form S-3, of our report dated December 22, 2014 relating to the consolidated financial statements, which appears in General Employments Enterprises, Inc.’s Annual Report on Form 10-K for the years ended September 30, 2014 and 2013.  We also consent to the reference to us under the heading “Experts” in such Registration Statement.

 
GEE OPINION OF LOEB & LOEB LLP

2017-06-21 sec.gov
EXHIBIT 5.1     345 Park Avenue New York, NY 10154-1895 Direct Main  Fax 212.407.4000 212.407.4000 212.407.4990    May 11, 2015   General Employment Enterprises, Inc. 184 Shuman Blvd., Ste. 420   Naperville, Illinois 60563   Re: General Employment Enterprises, Inc.   Ladies and Gentlemen:   We have acted as securities counsel for General Employment Enterprises, Inc., an Illinois corporation (the “Company”), in connection with the preparation and filing by the Company of a registration statement

Related Articles

ACIA: Acacia Communications Analysis and Research Report

6m - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...